The DOI matches its Crossref record.
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Open accessAbstract
Purpose: To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). Patients and Methods: In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult patients. In the first cohort, patients received 2 mg/kg weekly for 4 weeks; in all other cohorts, an intrapatient dose-escalation schedule was used with increasing doses up to a maximum of 8 mg/kg. Patients with clinical benefit after one cycle of dacetuzumab were eligible for a second cycle. Results: In the 50 patients who received dacetuzumab, no dose dependence of adverse events (AEs) was observed. The most common AEs in ≥ 20% of patients were fatigue, pyrexia, and headache; most were grade 1 or 2. Noninfectious inflammatory eye disorders occurred in 12% of patients. AEs grade ≥ 3 occurred in 30% of patients and included disease progression, anemia, pleural effusion, and thrombocytopenia. Most laboratory abnormalities were grade 1 or 2; transient elevated hepatic aminotransferases occurred in 52% of patients. Two patients experienced dose-limiting toxicity: grade 3 conjunctivitis and transient vision loss in cohort (1), and grade 3 ALT elevation in cohort IV. The MTD of dacetuzumab was not established at the dose levels tested. Six objective responses were reported (one complete response, five partial responses). Tumor size decreased in approximately one third of patients. Conclusion: Dacetuzumab monotherapy was well tolerated in patients with NHL in doses up to 8 mg/kg/wk. Preliminary response data are encouraging and support additional studies of dacetuzumab in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 351
Metadata
- Authors
- Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., & Drachman, J. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-09-10
- Volume
- 27
- Issue
- 26
- Pages
- 4371-4377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110502317
- Cited by
- 188
- References
- 0
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2008.21.3017
- The paper
- Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., Harrop, K., Whiting, N., & Drachman, J. G. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.3017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.